Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15097933.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Infliximab, a chimeric mouse-human monoclonal antibody, blocks the action of tumor necrosis factor-alpha and is a highly effective treatment for several inflammatory disorders, including inflammatory bowel disease and rheumatoid arthritis. Although safety data are encouraging, immunosuppressive sequelae may result. We report the acute development of multiple squamous cell carcinomas and keratoacanthomas in a patient receiving infliximab for rheumatoid arthritis.
Medical subject headings
- Antibodies, Monoclonal
- Antirheumatic Agents
- Carcinoma, Squamous Cell
- Keratoacanthoma
- Skin Neoplasms